T-WAVE ALTERNANS (TWA) IS ASSOCIATED WITH CARDIOVASCULAR MORTALITY AND NSVT IN THE MERLIN-TIMI 36 TRIAL OF RANOLAZINE VERSUS PLACEBO IN PATIENTS WITH NON-ST SEGMENT elevation ACUTE CORONARY SYNDROME

Overall, ranolazine did not reduce TWA between Days 1 and 6, although exploratory analyses suggest a reduction in TWA in pts with elevated baseline TWA >=47µV. Conclusions (1) In pts with NSTEACS, TWA >=47 µV on Day 1 is associated with increased risk of total and CV mortality and NSVT at 1 ye...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2013-03, Vol.61 (10), p.E257-E257
Main Authors: Scirica, Benjamin, Nieminen, Tuomo, Pegler, Jose RM, Tavares, Caio, Pagotto, Vitor PF, Kanas, Alexandre F, Sobrado, Marcel F, Nearing, Bruce, Cho, Ji, Morrow, David, Belardinelli, Luiz, Verrier, Richard
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Cardiology
Cardiovascular
Heart attacks
Internal Medicine
Mortality
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overall, ranolazine did not reduce TWA between Days 1 and 6, although exploratory analyses suggest a reduction in TWA in pts with elevated baseline TWA >=47µV. Conclusions (1) In pts with NSTEACS, TWA >=47 µV on Day 1 is associated with increased risk of total and CV mortality and NSVT at 1 year; (2) In pts with persistently elevated TWA, treatment with ranolazine may modify risk of mortality over 1 year, although further validation is needed.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(13)60257-0